Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
0.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.32%
median of 697 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Market Cap
$412.14M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
12.37%
Market Cap
$416.33M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$409.27M
Gross Margin
77.34%
TTM Avg
76.74%
3Y Avg
77.57%
5Y Avg
77.57%
Market Cap
$423.49M
Gross Margin
61.77%
TTM Avg
80.89%
3Y Avg
90.44%
5Y Avg
-1369.52%
Market Cap
$402.82M
Gross Margin
68.83%
TTM Avg
69.91%
3Y Avg
69.67%
5Y Avg
69.68%
Market Cap
$397.78M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$435.40M
Gross Margin
42.92%
TTM Avg
41.39%
3Y Avg
40.24%
5Y Avg
40.24%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neurogene Inc. (NGNE) | $416.01M | 0.00% | 0.00% | 0.00% | 0.00% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.14M | 0.00% | 0.00% | 0.00% | 12.37% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $416.33M | 0.00% | 0.00% | 0.00% | 0.00% |
| Shoulder Innovations, Inc. (SI)vs › | $409.27M | 77.34% | 76.74% | 77.57% | 77.57% |
| Carlsmed, Inc. (CARL)vs › | $404.24M | 76.63% | 74.56% | 73.66% | 73.66% |
| Prothena Corporation plc (PRTA)vs › | $423.49M | 61.77% | 80.89% | 90.44% | -1369.52% |
| Myriad Genetics, Inc. (MYGN)vs › | $402.82M | 68.83% | 69.91% | 69.67% | 69.68% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $397.78M | 0.00% | 0.00% | 0.00% | 0.00% |
| NeoGenomics, Inc. (NEO)vs › | $435.40M | 42.92% | 41.39% | 40.24% | 40.24% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $388.79M | 0.00% | 0.00% | 25.00% | 40.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 11.68% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
